Beyond basics: Key mutation selection features for successful tumor‐informed ctDNA detection
Open Access
- 16 April 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (5) , 925-933
Abstract
Tumor‐informed mutation‐based approaches are frequently used for detection of circulating tumor DNA (ctDNA). Not all mutations make equally effective ctDNA markers. The objective was to explore if prioritizing mutations using mutational features—such as cancer cell fraction (CCF), multiplicity, and error rate—would improve the success rate of tumor‐informed ctDNA analysis. Additionally, we aimed to develop a practical and easily implementable analysis pipeline for identifying and prioritizing candidate mutations from whole‐exome sequencing (WES) data. We analyzed WES and ctDNA data from three tumor‐informed ctDNA studies, one on bladder cancer (Cohort A) and two on colorectal cancer (Cohorts I and N). The studies included 390 patients. For each patient, a unique set of mutations (median mutations/patient: 6, interquartile 13, range: 1–46, total n = 4023) were used as markers of ctDNA. The tool PureCN was used to assess the CCF and multiplicity of each mutation. High‐CCF mutations were detected more frequently than low‐CCF mutations (Cohort A: odds ratio [OR] 20.6, 95% confidence interval [CI] 5.72–173, p = 1.73e−12; Cohort I: OR 2.24, 95% CI 1.44–3.52, p = 1.66e−04; and Cohort N: OR 1.78, 95% CI 1.14–2.79, p = 7.86e−03). The detection‐likelihood was additionally improved by selecting mutations with multiplicity of two or above (Cohort A: OR 1.55, 95% CI 1. 14–2.11, p = 3.85e−03; Cohort I: OR 1.78, 95% CI 1.23–2.56, p = 1.34e−03; and Cohort N: OR 1.94, 95% CI 1.63–2.31, p = 2.83e−14). Furthermore, selecting the mutations for which the ctDNA detection method had the lowest error rates, additionally improved the detection‐likelihood, particularly evident when plasma cell‐free DNA tumor fractions were below 0.1% (p = 2.1e−07). Selecting mutational markers with high CCF, high multiplicity, and low error rate significantly improve ctDNA detection likelihood. We provide free access to the analysis pipeline enabling others to perform qualified prioritization of mutations for tumor‐informed ctDNA analysis.Keywords
Funding Information
- Novo Nordisk Fonden (NNF17OC0025052, NNF22OC0074415)
- Kræftens Bekæmpelse (R133‐A8520‐00‐S41, R146‐A9466‐16‐S2, R231‐A13845, R257‐A14700)
- Innovationsfonden (9068‐00046B)
This publication has 37 references indexed in Scilit:
- NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA2023
- Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancerAnnals of Oncology, 2022
- Quantitative models for the inference of intratumor heterogeneityComputational and Systems Oncology, 2022
- DeCiFering the elusive cancer cell fraction in tumor heterogeneity and evolutionCell Systems, 2021
- Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomesCell, 2021
- Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survivalAnnals of Oncology, 2020
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal CancerJAMA Oncology, 2019
- Clinical factors associated with circulating tumor DNA (ctDNA) in primary breast cancerMolecular Oncology, 2019
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic LeukemiaCell, 2013
- Clonal evolution in cancerNature, 2012